NCT06580418招募中不适用
Evaluation of an Anti-TREM-1 Treatment on an ex Vivo Human Intestinal Model
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- Inotrem
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Collection of IBD patient-derived intestinal mucosal explants for testing TREM-1 antagonist
研究概览
简要总结
TIME is an observational study performed on UC and CD patients under endoscopic surveillance for monitoring the clinical activity of their disease.
The main objective of the study is to confirm the therapeutic potential of TREM-1 in inflammatory bowel disease.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients between 18 and 60 years
- •Signed informed consent
- •Ulcerative colitis (UC) patients with active disease
- •Crohn's disease (CD) patients with active disease
排除标准
- •UC or CD patients in remission
- •Patients between 18 and 60 years without informed consent
结局指标
主要结局
Collection of IBD patient-derived intestinal mucosal explants for testing TREM-1 antagonist
时间窗: 20 months
Derivation of RNA and proteins from biopsy specimens upon in vitro exposure to the TREM-1 antagonist
次要结局
- Concentration of pro-inflammatory cytokines in supernatants of treated explants to evaluate the effect of the TREM-1 antagonist compound(26 months)
- Gene expression in treated explants and other samples to evaluate the effect of the TREM-1 antagonist compound(26 months)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced SubjectsMultiple SclerosisNCT01624714Samuel Forrester Hunter, MD, PhD60
已完成
2 期
Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTRTransthyretin AmyloidosisNCT05635045Columbia University10
招募中
不适用
Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target TherapyBreast CancerNCT05754502Consorzio Oncotech300
已完成
2 期
Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)Lymphoma, Non-HodgkinNCT00094848Human Genome Sciences Inc.
Unknown
不适用
An Observational Study of Ertapenem in Outpatient Parenteral Antibiotic Therapy (OPAT) for Complicated Urinary Tract Infections.Urinary Tract InfectionsNCT01173068National University Hospital, Singapore60